AACR 2022 | Highlights from AACR 2022 for gastric cancers

Michael Cecchini, MD, Yale School of Medicine, New Haven, CT, shares his highlights from this year’s AACR Annual Meeting. The development of novel combination therapies in a post-immune checkpoint inhibition era is a promising area of research that has opened the possibility to re-sensitize treatment resistant malignancies. In particular, the targeting of cancers with ataxia telangiectasia mutated (ATM) loss of function or high mutation rates with ataxia-telangiectasia and Rad3 related (ATR) inhibition could have a significant impact in gastric cancer, with 10% of patients having ATM loss of function. This interview took place at the American Association for Cancer Research Annual Meeting 2022 in New Orleans, LA.